@article{Sypalo_Kravchun_Kadykova_Pashtiani_2021, title={Comparative characteristics of application of statins in combination with fibrates and omega-3 polyunsaturated fatty acids in patients with coronary heart disease and type 2 diabetes mellitus}, volume={61}, url={https://www.jpep.endocrinology.org.ua/index.php/1/article/view/292}, DOI={10.21856/j-PEP.2017.3.09}, abstractNote={<p>The comparative characteristic of application of statins in combination with fibrates and omega-3 polyunsaturated fatty acids in patients with coronary heart disease and type 2 diabetes mellitus were hold in the article. The study included 75 patients with CHD and type 2 diabetes mellitus, who were divided into two subgroups depending on the received lipid-lowering therapy. The first subgroup included 37 patients with coronary heart disease and concomitant type 2 diabetes mellitus, who in order to low the lipid level received atorvastatin in dose of 20 mg per day and fenofibrate at a dose of 14 mg per day after dinner. The second subgroup included 38 patients with the same nosological units who received atorvastatin in dose of 20 mg / day and omega-3 polyunsaturated fatty acids at a dose of 1000 mg in the morning and in the evening. The study demonstrated a positive effect of combinations of lipid-lowering therapy on lipid metabolism in the form of atorvastatin with fibrates and omega-3 polyunsaturated fatty acids in patients with coronary heart disease and type 2 diabetes mellitus due to the reduction of atherogenic fractions and increase of proatherogenic ones. According to the results of our study any significant differences of lipidogram depending on the lipid-lowering therapy schemes (atorvastatin and fibrates; atorvastatin and omega-3 polyunsaturated fatty acids) in patients with coronary artery disease and type 2 diabetes mellitus has not been established, but there was a trend to increase the level of HDL cholesterol in patients treated with omega-3 polyunsaturated fatty acids in addition to statin and to reduce TG in patients treated with fibrates in combination with statins. </p>}, number={3}, journal={Problems of Endocrine Pathology}, author={Sypalo, A. O. and Kravchun, P. G. and Kadykova, O. I. and Pashtiani, R. V.}, year={2021}, month={Jun.}, pages={65-70} }